-
Loading metrics
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease
-
William C. Reisdorf ,
Contributed equally to this work with: William C. Reisdorf, Qing Xie
Roles Investigation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: william.c.reisdorf@gsk.com
Affiliation Computational Biology, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
⨯ - Qing Xie ,
- Xin Zeng,
- Wensheng Xie,
- Neetu Rajpal,
- Bao Hoang,
- Mark E. Burgert,
- Vinod Kumar,
- Mark R. Hurle,
- Deepak K. Rajpal,
- Sarah O’Donnell,
- Thomas T. MacDonald,
- Anna Vossenkämper,
- Lin Wang,
- Mike Reilly,
- Bart J. Votta,
- Yolanda Sanchez,
- [ ... ],
- Pankaj Agarwal
- [ view all ]
- [ view less ]
http://orcid.org/0000-0001-9411-0179
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease
- William C. Reisdorf,
- Qing Xie,
- Xin Zeng,
- Wensheng Xie,
- Neetu Rajpal,
- Bao Hoang,
- Mark E. Burgert,
- Vinod Kumar,
- Mark R. Hurle,
- Deepak K. Rajpal
x
- Published: April 19, 2019
- https://doi.org/10.1371/journal.pone.0215033